Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome.
Phase of Trial: Phase IV
Latest Information Update: 19 Nov 2014
At a glance
- Drugs Ramosetron (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 21 May 2013 Results presented at the Digestive Disease Week 2013.
- 19 Sep 2011 Actual end date 1 Aug 2011 added as reported by ClinicalTrials.gov.
- 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.